McArthur Translational Neuroimaging

Tools for CNS Drug Discovery, Development and Treatment
1. Auflage 2012
ISBN: 978-0-12-386997-5
Verlag: Elsevier Science & Techn.
Format: EPUB
Kopierschutz: 6 - ePub Watermark

E-Book, Englisch, 464 Seiten

Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment combines the experience of academic, clinical and industrial neuroimagers in a unique collaborative approach to provide an integrated perspective of the use of small animal and human brain imaging in developing and validating translational models and biomarkers for the study and treatment of neuropsychiatric disorders. Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment examines the translational role of neuroimaging in model development from preclinical animal models, to human experimental medicine, and finally to clinical studies. The focus of this book is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This book covers methodical issues in human and animal neuroimaging translational research as well as detailed applied examples of the use of neuroimaging in neuropsychiatric disorders and the development of drugs for their treatment. Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment appeals to non-clinical and clinical neuroscientists working in and studying neuropsychiatric disorders and their treatment as well as providing the novice researcher or researcher outside of his/her expertise the opportunity to understand the background of translational research and the use of imaging in this field. - Provides a background to translational research and the use of brain imaging in neuropsychiatric disorders - Critical discussion of the potential and limitations of neuroimaging as a translational tool for identifying and validating biomarkers - Identifies cross species neurosystems and common endpoints necessary to help accelerate CNS drug discovery and development for the treatment of neuropsychiatric disorders

Autoren/Hrsg.

McArthur, Robert A.

Leseproben

Abbreviation List
A number of abbreviations and acronyms are used throughout the book and are defined within the text. However, for the ease of the reader, these abbreviations and acronyms are listed below. 1H-MRS    proton MRS 2-DG    2-deoxyglucose 3D    three-dimensional 3DTI    three-dimensional T1-weighted DTI 5-HT    5-hydroxytryptamine (serotonin) 5-HTTR or HTT    5-HT transporter 11C-PiB    N-methyl-[11C]2-(4’-methylaminophenyl)-6-hydroxybenzothiazole 123I-IBZM    123I-benzamide, dopamine D2 ligand Aß    ß-amyloid; Aß1–42 AAL    Automatic Anatomic Labeling ACC    anterior cingulate cortex ACG    anterior cingulate gyrus AD    Alzheimer disease ADAS-cog    Alzheimer’s Disease Assessment Scale-cognitive subscale ADAS-J-cog    Japanese version of the ADAS-cog ADC    Apparent diffusion coefficient ADCS    Alzheimer’s Disease Consortium Study AddNeuroMed    Innovative Medicines Initiative, consortium to find a biomarker for Alzheimer disease ADI-R    Autism Diagnostic Interview-Revised ADNI    Alzheimer’s Disease Neuroimaging Initiative AEP    auditory evoked potential AFNI    analysis of functional neuroimages AH    allostatic hypotheses AIBL    Australian Imaging Biomarkers and Lifestyle (Flagship Study of Ageing) AIR    automatic image registration aMCI    amnestic mild cognitive impairment AMPT    alpha-methyl-para-tyrosine ANOVA    analysis of variance ApoE    apolipoprotein E, APOE e4 allele APP    amyloid precursor protein APTD    Acute Phenylalanine/Tyrosine Depletion ASD    autistic spectrum disorders ASL    arterial spin labeling ATP    adenosine triphosphate ATR    antidepressant treatment response AUC    area under the curve AV-45    Florbetapir or Amyvid AVLT    auditory verbal learning test B0    main static magnetic field B1    magnetic field associated with radiofrequency pulse BA25    Brodmann Area 25 BAL    blood alcohol level BBSI    brain boundary shift integral BDNF    brain-derived neurotrophic factor BLSA    Baltimore Longitudinal Study of Aging BOLD    blood oxygenation level dependent BP    binding potential BSI    boundary shift integral CAA    cerebral amyloid angiopathy CAMD    Coalition Against Major Diseases CASL    continuous ASL CBF    cerebral blood flow CBV    cerebral blood volume CDFE    cortical dysplasia-focal epilepsy CDR    Clinical Dementia Rating CDR-sb or CDR-SOB    CDR sum of boxes subtest CERAD    Consortium to Establish a Registry for Alzheimer’s Disease CHMP    Committee for Medicinal Products for Human Use Cho    Choline CMRglc    cerebral metabolic rate for glucose CMRO2    cerebral metabolic rate of oxygen CNR    contrast-to-noise CNS    central nervous system CNTNAP2    contactin-associated protein-like 2 COMT    catechol-O-methyltransferase CORT    corticosterone Cr    creatine CREB    cyclic AMP-responsive element-binding protein CS    conditioned stimulus CSF    cerebrospinal fluid CT    computed tomography, also X-ray computed tomography DA    dopamine dACC    dorsal anterior cingulate cortex DAT    dopamine transporter DDNP    1,1-dicyano-2-[6-(dimethylamino)-2-naphthalenyl]propene DEAF-1    deformed epidermal autoregulatory factor-1 DISC1    disrupted-in-schizophrenia 1 DLPFC    dorsolateral PFC DMN    default mode networks DMPFC    dorsomedial PFC DS    dorsal striatum DSM-IV-TR    Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision DTI    diffusion tensor imaging DVR    distribution volume ratio(s) DW-MRI    diffusion weighted MRI ECT    electroconvulsive therapy EEG    electroencephalography EMA    European Medicines Agency EPI    echo-planar imaging ERD    event-related desynchronization ERP    event related potential ERS    event-related synchronization EtOH    ethanol FA    fractional anisotropy FAQ    functional activities questionnaire FBP    filtered back projection FDA    US Food and Drug Administration FDDNP    (2-(1-{6-[(2-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile) FDG    18F-flurodeoxyglucose fMRI    functional MRI FMRP    fragile X mental retardation protein FOV    field of view FT    Fourier transform FTD    frontotemporal dementia FTLD    frontotemporal lobar degeneration FXS    fragile X syndrome GABA    ?-aminobutyric acid GABRA2    a2 GABA receptor subunit GBD    glutamate-based depression GD    gestational day Gln    glutamine Glu    glutamate Glx    glutamate/glutamine mix GM    gray matter GMP    Good Manufacturing Practices GWAS    genome-wide association studies HAD    high alcohol drinking rat HASTE    half-Fourier acquisition single-shot turbo spin echo Hb    oxygenated hemoglobin dHb    deoxygenated hemoglobin HC    healthy control HCV    hippocampal volume HIF-1    hypoxia-inducible factor 1 HOC    hippocampal occupancy HPA    hypothalamic-pituitary-adrenal IACC    Interagency Autism Coordinating Committee ICA    independent component analysis ICC    intraclass correlations IFN    interferon IGT    Iowa Gambling Task IMI    Innovative Medicines Initiative IQ    intelligence quotient LAD    low alcohol drinking rat IAPS    international affective picture series LCGU    local cerebral glucose utilization LDA    linear discriminant analysis LDAEP    loudness dependence of the auditory evoked...